Abstract Purpose: To determine whether published cost^effectiveness studies on inhaled corticosteroids (ICS) in asthma adhered to basic analytical standards as defined in health economic textbooks and in guidelines assessing and comparing efficacy and safety. Methods: Original cost^effectiveness studies published between1990 and 2000 in general medical or economic journals were reviewed to assess the adherence to five fundamental methodological principles: (1) design of the study, (2) choice of perspective and corresponding costs, (3) choice of outcome measure, (4) marginal cost analysis, and (5) sensitivity analysis and discussion about external validity. For each principle, the studies were ranked as high, medium or low quality. Results: Most of the18 studies included were ranked medium on the firsttwo principles.The studies adhered to a higher degree to the remaining three principles.Only three studies were high ranked in all five principles.The number of principles fulfilled increased over time. Studies comparing pharmaceutical products from competing companies were typically short-term studies, designed for other purposes than health economic analyses, and, in general, did not use therapeutically equivalent dosing. Conclusions: Attention should be drawn to the study design, the weak correspondence between perspective and costs, and especially to the impact of bias in health economic results when comparing different doses of ICSs. r
INTRODUCTION
Cost^e¡ectiveness analysis is currently an accepted analytical technique to establish the relationship between costs and e¡ectiveness of a particular intervention. In pharmaco-economics, cost^e¡ectiveness analysis is used to assess if one drug (or combination of drugs) is more cost-e¡ective than another under similar circumstances. Pharmacoeconomic studies are often an important component in price-regulation and reimbursement decisions, as well as in drug formulary listings and marketing. Hence, several countries have developed guidelines for performing such studies [see (1) for an overview].
Inhaled corticosteroids (ICS) were introduced in 1972 and were at ¢rst limited to the treatment of severe asthma. In the second half of the 1980s, increased understanding that asthma is an in£ammatory disease and that ICS have an anti-in£ammatory e¡ect developed. More recently, studies demonstrated that ICS therapy reduces the risk of asthma-related hospitalisation and outpatient visits (2^4).
Published review articles suggest that the acquisition cost of ICS can be o¡set by a reduction in other healthcare costs (5, 6) . However, few reviews examined the methodologies used in the health economic studies on asthma, which is important in order to give decision-makers in health service assistance in interpreting results. One exception was Buxton (7) , who concluded that scarcity of cost^e¡ectiveness studies partly was due to the di⁄culty of de¢ning an outcome measure that captures the multidimensional e¡ects of respiratory interventions. The National Asthma Education and Prevention Program Working Group conducted a review of the literature on cost^e¡ectiveness of asthma patient education programmes, pharmaceutical therapy, and a variety of alternative and adjunct interventions (8) .They revealed many shortcomings and a lack of standard approach to evaluate the cost^e¡ectiveness of medical technologies in asthma.
Although guidelines exist for cost^e¡ectiveness studies, few attempts have been made to evaluate the analytical standards and adherence to basic costê ¡ectiveness principles in the area of asthma treatment. The purpose of this study was to examine whether published cost^e¡ectiveness studies on ICS in asthma, published up to the year 2000, adhered to basic analytical standards as de¢ned in economic textbooks and guidelines.
METHODS

Article selection
Articles published 1990^2000 were drawn from a Medline and Embase literature search using 15 keywords* related to ICS treatment for asthma. To simplify the analysis of this study only full-length (no abstracts), original cost^e¡ectiveness studies based on data from randomised clinical trials (RCTs) were considered. Cost of illness and cost minimisation studies, review articles, and studies on e⁄cacy without any attempt to provide information on costs were excluded.
Methodological review
To identify principles appropriate for cost^e¡ectiveness analysis and economic evaluation of healthcare practices in general, a literature review of guidelines and health economic textbooks was performed (9^14). Variables such as the clinical trial design, choice of comparator, cost and perspectives, results presentation and sensitivity, are evaluated. However, the therapeutic e¡ect of inhaled agents is in£uenced by a number of factors, not only the pharmacological potency, but also the doses used, the treatment duration and the amount reaching the airways and lungs, the latter depending on the type of inhaler used. Hence, a review of guidelines on how to assess and compare the underlying ICS e⁄cacy and safety data (8,15^17) complements the economic guidelines.
On the basis of this literature, ¢ve principles thought to comprise a high standard that cost^e¡ectiveness studies should be expected to follow were identi¢ed: (1) design of the study; (2) choice of perspective and corresponding costs; (3) choice of outcome measure; (4) description of the costing methods and marginal cost analysis; and (5) sensitivity analysis and discussion of external validity. As each principle not necessarily has the same weight, we present the results of each principle in a disaggregate form.
Design of the study
Adherence to good practice in designing trials for investigating alternative treatments of asthma was evaluated on four basic criteria. First, the study should be designed as a parallel-group RCTand not as, e.g., a crossover trial in which subjects serve as their own control. The crossover design is less accepted for asthma trials comparing ICS because therapeutic e¡ects of variable persistence may spill over from the ¢rst treatment to the administration of the second (16) . Second, to account fully for the costs and e¡ects of an intervention, results should be reported for the entire sample of recruited patients, i.e., an intention-to-treat analysis (8) . In addition, costs included should not be driven by the trial itself. Hence, the economic analysis should at least have been planned and coordinated with the RCT, i.e., it should have had an impact on the study design. Third, as asthma is a chronic disease, the follow-up period should be long enough to allow assessment of e¡ectiveness, possible dropouts and costs (8) . We required a study period of at least 6 months, the same requirement as in an evaluation by the Swedish Council on Technology Assessment in Health Care (18) .
Finally, the choice of dosage in£uences not only clinical and health outcomes, but also has an impact on the costê ¡ectiveness ratio. Although a doubling of doses may have a modest e¡ect on clinical or health outcomes, it nevertheless doubles the medication cost. As drug costs normally represent most healthcare costs in mild and moderate asthma (19, 20) , cost^e¡ectiveness ratios could be heavily biased when inappropriate dose combinations are used. It is beyond the scope of this study to fully evaluate the appropriate comparison of dose combinations. However, we have used a de¢nition of therapeutically equivalent dose between £uticasone proprionate (FP) and budesonide (BUD) if the FP:BUD dose ratio was 1:2 or less when a pressurised metered dose inhaler (pMDI) was used. If the drugs were inhaled through a dry-powder inhaler (DPI), e.g., Diskhaler orTurbuhaler, the corresponding equivalent dose ratio was de¢ned as 1:1 (15, 21, 22) . Dosages in studies comparing another ICS with BUD or FP were accepted since we were unable to ¢nd similar dose equivalents.
If all four criteria were ful¢lled we ranked the study high. Consequently, a study was ranked low/medium if neither/some of the criteria was/were met.
Choice of perspective and corresponding costs
Cost^e¡ectiveness analysis can be undertaken from a number of di¡erent perspectives. The societal perspective is the most comprehensive and incorporates, in theory, all costs and all health e¡ects regardless of who incurs the costs and who obtains the bene¢ts. Other commonly used perspectives are those of the government, healthcare institutions (e.g., hospital or clinic), third-party payer, and patient and family. The choice of perspective has important methodological rami¢ca-tions, and, as the included cost items di¡er between perspectives, the cost^e¡ectiveness ratios will change with the perspective chosen.
We demanded a high ranked study to make it obvious what perspective was chosen and that costs included in the analyses corresponded to the perspective. If costs did not correspond to the perspective chosen, or if the perspective was not discernible, the study was ranked medium and low, respectively.
Choice of outcome measure
It is often recommended that choice of e¡ectiveness measure should relate to a ¢nal health outcome such as life-years saved or healthy days gained (9) .The numerous outcome measures for asthma can roughly be categorised into ¢ve key outcomes (8): clinical and symptom measures (exacerbations, symptom-free days, etc.), physiological measures [surrogate endpoints, e.g., peak expiratory £ow (PEF)], quality-of-life measures, patient management (behavioural change and compliance), and health services utilisation, e.g., the number of hospital visits.
Surrogate endpoints must be explicitly related to some health bene¢t since it is health per se that should be maximised. In one in£uential article on outcomes measure in health economic analysis, it was concluded that surrogate endpoints cannot be recommended in cost^e¡ectiveness analysis (13) , which corresponds to the statement in the consensus report from the European experts on methodological issues. According to this document, ''surrogate endpoints are not recommended as e¡ectiveness measures of cost^e¡ectiveness analyses unless (a) they have a clear meaning to decision makers, (b) they are unambiguously correlated with health status and capture all the relevant di¡erential effects on the outcomes of the options compared'' (14) .
This review distinguished between physiological (surrogate) endpoints and (non-surrogate) health-related outcomes without regarding the appropriateness of the measures used. To receive a high rank, a health-related outcome measure should be reported. If only other types of outcomes were reported, the study was ranked low (this principle has no medium rank).
Description of the costing methods and marginal cost analysis
Costs should ideally re£ect the value of the input in its best alternative use. Unit prices for inputs and medical procedures do not necessarily re£ect the minimum cost as they could be based on average costs, and not patientspeci¢c costs. Another way is to use charges or fees, e.g., for hospital admissions for studies in the United States, but the usual approach is to use cost-to-charge ratio to convert billing information into economic cost estimates (10) . A third alternative, often used in Europe, is to use accounting costs, e.g., for a physician visit. A fourth approach is to conduct a whole cost estimation, based on information about inputs such as salary cost per time unit, cost of facilities, administration, etc.
When comparing two healthcare programmes, the incremental cost^e¡ectiveness ratios (ICER) is the appropriate measure (9, 10, 14, 23) . When choosing between di¡erent technologies, the ICER tells us cost per unit of bene¢t when switching from one treatment to another, e.g., incremental cost per symptom-free day gained. Average cost, on the other hand, re£ects the cost per bene¢t independent of other treatments.
To be ranked high, we required that a study present su⁄cient information for assessing the costing methods and that the ICER approach was used in case one alternative was not dominant w . If only one of these criteria was ful¢lled, the study was ranked medium, and if none was ful¢lled, the study was ranked low.
Sensitivity analysis and discussion of external validity
Conventional statistical methods are only applicable if the data are sampled. In cost^e¡ectiveness studies, data are often sampled for some items of resource use, e.g., number of physician visits, days in hospitals, etc. However, costs are often generated from other sources. Sensitivity analysis is therefore the primary method for allowing for uncertainty in economic evaluations (9) . By varying a single or multiple (more thorough) variables at a time, the sensitivity of the results is studied. Furthermore, data from RCTs may have a low degree of external validity due to a strict research protocol. Therefore, a discussion on the ability to generalise the results to the real-world setting is important.
Both a discussion about the external validity and sensitivity analysis (regardless of single-or multi-dimensional) were necessary to achieve a high rank. If only one or none of these was reported, the study was ranked medium or low, respectively.
Analysis
We ranked the ¢ve principles as high, medium or low based on the aforementioned criteria. For each of the ¢ve principles, the articles were then compared by type of journal publication, whether the study compared two w ''Dominant'' indicates an alternative that is both less costly and produces a better outcome than the other alternative(s).
or more competing products, by the pharmaceutical company sponsoring the study, and by the year of publication (old: 1993^1996; new: 1997^2000). These comparisons were chosen to reveal methodological differences in medical and non-medical journals, in studies comparing doses of the same product or competing products, whether the stakeholders could have had an impact, and if there has been a growing awareness for health economic methods over time.
RESULTS
Article selection
The literature search generated 194 matching articles but included many articles without any cost^e¡ective-ness analysis and reviews; therefore, only 46 articles were further considered. Of these, another 30 papers were rejected as they were descriptive cost of illness analyses, reviews or meta-analyses, or did not include a comparison of alternative treatments. Another two articles were found in the articles' reference lists. Hence,18 articles were included in this analysis (see reference list).
Eight studies evaluated a single ICS: two compared BUD vs. usual care without ICS, four compared di¡erent doses of BUD, one compared di¡erent doses of FP and one compared FP vs. a combination of FP and a b 2 -agonist. In one study, a combination of b 2 -agonist/ anticholineric therapy was compared with a combination of b 2 -agonist/ICS therapy (classi¢ed in this review as competing products). In the other nine studies, two ICS were compared. Six of these studies compared FP vs. BUD; in four of them a DPI was used as the inhaler device, and, in the other two studies, two di¡erent inhaler devices were used, e.g., pMDIvs. DPI.The remaining three studies compared FP vs. sodium cromoglycate, FP vs. triamcinolone acetonide and FP vs. £unisolide, respectively.
Ten articles were found in economic journals, and eight were published in medical journals. Six articles were sponsored by AstraZeneca (AZ) and 10 by Glaxo Wellcome (GW). The remaining two studies received grants from several sources. z For the two principles, design and costs corresponding to the perspective chosen, most studies were ranked medium ( Table 1 ). Short length of study (11 studies) and design mainly for other purposes than economic evaluation (10 studies) reduced the scores. One study had a cross over design. For the remaining three principles, the studies adhered in a higher degree to the requirements.
Only three studies were highly ranked in all ¢ve principles (Table 2) . One study was ranked high on four principles and medium on one principle. Studies comparing competing products were to a higher degree sponsored by GW, were published more recently and had a shorter study period than the non-competing product studies. Older studies were predominantly published in economic journals.
Design
The median length of the underlying RCTs were 3 months (mean length, 7.2 months; range, 1^30 months), and only seven studies had a study period of at least 6 months. All articles provided information on dosing, but four of the 10 studies comparing alternative ICS did not ful¢l the requirements for therapeutically equivalent dosing.
}
Ten studies were originally designed for purposes other than economic analysis, of which seven were found in the competing-drugs studies. Only one study was designed for economic analysis. Studies published in medical journals were based more often on RCTs with a longer study period and studies not comparing competing drugs ful¢lled the criteria of equivalent dosing to a higher degree (Fig.1) .
Perspective chosen and corresponding costs
Fourteen studies stated a national healthcare system, societal or third-party payer perspective. In the 1993 1993 1993 1995 1995 1996 1996 1996 1997 1997 1998 1998 1998 1999 1999 1999 
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remaining four studies, the perspective was unknown. Overall, only six of the studies managed to cost the resource consumption in accordance with the perspective taken, which drives the results depicted in Fig. 2 .This de¢-ciency was mainly due to a lack of information about whether adjustments for patient co-payments were made. The competing-drugs group attained the lowest scores due to non-explicit perspective and non-corresponding costs.
Outcome measure
In the 18 articles reviewed, 16 di¡erent outcome measures (11 surrogate and ¢ve health-related outcomes) were used, of which eight were used in more than one article. The most frequently used measure was symptom-free days (11articles). Another three measures were used in three or more articles. The de¢nition of a symptom-free day varied between articles (and study arms in one article), as did the de¢nition of ''success'' among the surrogate endpoints (e.g., PEF 490% or PEFX95% of predicted).
Three articles did not present any health-related outcomes, whereas two studies reported such measures only. Hence, the reviewed articles adhered well to the standards (Fig. 3) .
Marginal costing analysis
Information on costing methods was provided in all but two studies, and ¢ve articles presented average cost analysis only. Overall, the costing method and the marginal analysis adhered well to what could be expected from a cost^e¡ectiveness study.
Newer articles performed better than older articles due to a more detailed presentation of costing methods and of incremental cost^e¡ectiveness ratios (Fig. 4) . In four studies comparing competing products, only average cost^e¡ectiveness ratios were presented.
Sensitivity analysis and external validity discussion
Sensitivity analysis and discussion of external validity were reported in 13 and11of the18 articles, respectively. Newer articles, articles comparing competing products and GW-sponsored articles discuss the external validity of the results more frequently than older studies (Fig. 5) .
DISCUSSION
Eighteen original health economic studies on inhaled ICS for treatment of asthma were evaluated according to analytical standards. Evaluation was based on conformance with ¢ve basic principles commonly found in the health economic literature and speci¢c guidelines on how to scienti¢cally assess and compare ICS e⁄cacy and safety. This study does not claim to be comprehensive, as it is speci¢cally limited to original cost^e¡ective-ness studies based on RCT. However, with slight modi¢cations of the criteria, the principles can be applied to evaluations of other pharmaceutical programmes.
Low High
Outcome Measure In order to avoid the complex concept of quality we have used simply binary (high^low) method of analysis. We have not considered whether the criteria/principles are ''very well'' or ''barely'' ful¢lled. Hence, great variation prevails within our grading. No ranking or weights has been assigned to the principles. This methodology leaves room for more through quality analysis, which is beyond the aim of this study. However, we believe this analysis brings forward some potential problems and caveats to bear in mind in spite of the limited number of studie cost^e¡ectiveness articles. In four of the principles for cost^e¡ectiveness analysis, principles 2^5, the ranking of the studies increased over time. This could re£ect the greater awareness of the common principles for conducting health economic analyses among authors and/or reviewers.
The most frequently occurring shortcoming was the lack of correspondence between costs and perspective. For example, some studies stated a third-party payer perspective but included patient co-payments in the cost for pharmaceuticals.Other examples showed that even if a national healthcare perspective was chosen, the analysis did not include costs other than pharmaceuticals. In some studies, there was not even an attempt to estimate costs for health care other than medicines. Including non-relevant (or excluding relevant) costs drives the cost^e¡ectiveness ratio and can bias the results.
Design was another reason for a low ranking of several studies. With a median study period of 3 months, it was uncertain whether the full clinical e¡ect was attained and if relatively rare events such as hospitalisations were fully captured. An interesting observation was the correlation between low-scored studies relying on relatively short-term RCTs and low-scored studies on competing therapies.These short-term studies were not designed for economic purposes, and in neither of these studies did the costs correspond to the stated perspective.
Another serious design problem, and until recently a less noticed issue (17) , was the variation in dose ratios between FP and BUD (varied between 1:1 and 1:3.2). In the following hypothetical example, we discuss the issue of comparing appropriate doses when evaluating alternative ICS.
Assume that drugs A and B are priced the same per weight and that they have di¡erent dose^response curves in that drug A reaches a plateau earlier than drug B (Fig. 6) .The two compounds are evaluated at a dose relationship of 1:1, e.g., at dose x. Drug A would not be signi¢cantly more e¡ective than drug B, and the costs for the two alternative medicines would be the same. As a second case, assume that drug A would be administered at dose x, whereas drug B will be administered at dose y=2x, i.e., a double dose. A comparison of the two drugs at a dose relationship of 1:2 would result in a similar bene¢t for both treatment groups. However, as the drugs are priced exactly the same, the costs for the patient group receiving drug B will be twice as high as the costs for the patient group receiving drug A.
A cost^e¡ectiveness analysis using a1:2 dose relationship would then result in a disadvantage for drug B as a signi¢cant di¡erence in drug costs is compared with a non-signi¢cant di¡erence in bene¢ts. On the other hand, a cost^e¡ectiveness analysis using a 1:1 dose relationship would result in a more favourable outcome for drug B as the non-signi¢cant di¡erence in bene¢ts is attained at identical drug costs.The implication is that the choice of doses based on studies evaluating e⁄cacy and safety could result in biases in cost^e¡ectiveness studies.
The increased reporting of health outcomes should not be a goal per se. It is important that these measures (both surrogate and health-related) are standardised to enhance comparability between studies (8, 23) . If symptom-and episode-free days are used, it is imperative that the same de¢nition applies in all study-arms and that the scale is uniform. In addition, the lack of outcome uniformity infringes on the credibility through the impression that authors choose the most favourable outcome measure of the study, that is, only measures where signi¢cant di¡erences are detected.
CONCLUSION
Despite the fact that cost^e¡ectiveness studies of ICS for the treatment of asthma still su¡er from shortcomings in the outcomes measures used, adherence to analytical standards has increased over time. However, our review revealed shortcomings in methods for costing, design of the study in general and methods for comparing doses in particular.The choice of doses may cause bias in the cost^e¡ectiveness results and is therefore a threat to the validity when evaluating competing therapies.
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